Everything You Need to Know About the Approval of Lumateperone for Major Depressive Disorder

On November 6, 2025, the US Food and Drug Administration (FDA) approved Johnson & Johnson’s lumateperone (Caplyta) as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD).¹ Here's what you need to know: